Corporate Profile
Web Site:
Registration country:
United States
Industry:
Biotechnology
Overview
Glaukos Corp is committed to transforming glaucoma therapy. To this end, Glaukos is bypassing anatomical impediments and treatment conventions to develop treatments that restore natural physiologic outflow as a foundation of significant, steady and sustained glaucoma management. Today, they are at the beginning with an innovative micro technology. In collaboration with their clinician partners, they are building technology towards a safer and more effective treatment for preserving vision in patients with primary open-angle glaucoma.
Investors
| Investor | Profile | Amount | Stage | Date | ||
|---|---|---|---|---|---|---|
| Domain Associates LLC | Series D | 29th Aug 2008 | ||||
| Frazier Healthcare Ventures | Series D | 29th Aug 2008 | ||||
| InterWest Partners | Series D | 29th Aug 2008 | ||||
| MeriTech Capital Partners | ||||||
| Montreux Equity Partners | Series D | 29th Aug 2008 | ||||
| OrbiMed Advisors LLC | Series D | 29th Aug 2008 | ||||
| OrbiMed Advisors LLC | ||||||
| Versant Ventures | Series D | 29th Aug 2008 |
Current employees
No current employees available
RECORD ID: 288744